Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death.

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignant disease that is resistant to various chemotherapeutic agents and commonly relapses. Efficient elimination of metastasized PDA is critical for a positive post-surgical treatment outcome. The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death. A total of 8 PDA cell lines were subjected to immunoblotting to compare the expression of Bcl-2/Bcl-xL and other factors associated with taxane resistance, including myeloid cell leukemia 1 and βIII-tubulin (TUBB3). The viability of PDA cells was analyzed following treatment with paclitaxel alone or a combination treatment with ABT-737 and paclitaxel. Treatment with the ABT-737/paclitaxel combination induced PDA cell death at a lower concentration of paclitaxel compared with paclitaxel alone. In addition, the viable cell population at the saturation point of paclitaxel was also decreased by co-treatment with ABT-737. ABT-737 lowered the half maximal inhibitory concentration (IC50) by >2-fold in PDA cells with high Bcl-2/Bcl-xL expression, but not in PDA cells with low Bcl-2/Bcl-xL expression and high TUBB3 expression. Knockdown of Bcl-xL lowered the IC50 of paclitaxel, but knockdown of TUBB3 did not. ABT-737 sensitized PDA to paclitaxel-induced cell death, and Bcl-xL expression was a key determinant of its sensitivity. ABT-737 is potential candidate for combination chemotherapy of PDA with high Bcl-xL expression levels.

[1]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[2]  M. Meyer-Hermann,et al.  Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas , 2014, PloS one.

[3]  T. Masuda,et al.  BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells , 2013, Experimental dermatology.

[4]  K. Syrigos,et al.  Prognostic factors in pancreatic cancer. , 2013, JOP : Journal of the pancreas.

[5]  Fenghua Wang,et al.  Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer , 2013, Cancer Chemotherapy and Pharmacology.

[6]  M. Saif.  Advancements in the management of pancreatic cancer: 2013. , 2013, JOP : Journal of the pancreas.

[7]  J. Settleman,et al.  Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models , 2013, Molecular Cancer Therapeutics.

[8]  A. Richardson,et al.  Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. , 2013, Gynecologic oncology.

[9]  Manuel Hidalgo,et al.  Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas , 2012, Clinical Cancer Research.

[10]  F. Peale,et al.  Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models , 2012, Molecular Cancer Therapeutics.

[11]  A. Andrén-sandberg.  Prognostic Factors in Pancreatic Cancer , 2012, North American journal of medical sciences.

[12]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Rikiyama,et al.  Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study , 2011, International Journal of Clinical Oncology.

[14]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[15]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Zha,et al.  Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models , 2011, Clinical Cancer Research.

[17]  S. Gygi,et al.  SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction , 2010, Nature.

[18]  N. Boku,et al.  Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. , 2010, Japanese journal of clinical oncology.

[19]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[20]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[21]  R. Hruban,et al.  Class III β‐tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia , 2007, Histopathology.

[22]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Blagosklonny.  Mitotic Arrest and Cell Fate: Why and How Mitotic Inhibition of Transcription Drives Mutually Exclusive Events , 2007, Cell cycle.

[24]  J. Snyder,et al.  Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules , 2006, Molecular Cancer Therapeutics.

[25]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[26]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[27]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[29]  M. Relling,et al.  Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.

[30]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Wilson,et al.  Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies , 2011 .

[32]  Yonghong Xiao,et al.  SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .

[33]  M. Saif,et al.  Advancements in the management of pancreatic cancer. , 2009, JOP : Journal of the pancreas.

[34]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[35]  E. Martinelli,et al.  Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.